Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Outlines Two-year Development, Debt Reduction Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.

You may also be interested in...

Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation

Deal demonstrates strength of AstraZeneca’s patents, analyst says.

AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder

Firm looks to expand $4 billion franchise into lucrative MDD market.

AstraZeneca Tries For Seroquel XR Approvals In Europe

Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts